Therapeutics
Asthma and COPD for OPRA: Current Guidelines, Inhalers and MCQs
Asthma and COPD are two of the highest-yield respiratory topics on OPRA, and they're frequently tested together specifically because they're easy to confuse — similar symptoms, very different underlying mechanisms and drug backbones. This guide covers the current GINA anti-inflammatory-reliever approach, inhaler technique, and the adverse-effect pattern OPRA tests most.
Why this topic matters
Respiratory conditions are consistently one of the most heavily represented Therapeutics topics on OPRA, and asthma/COPD scenarios are a favourite way to test whether a candidate understands mechanism (why a drug is chosen) rather than just memorised drug names.
Learning objectives
- Explain why asthma and COPD have different drug treatment backbones despite similar presentations
- Describe the current GINA anti-inflammatory-reliever (AIR) and maintenance-and-reliever (MART) approach to asthma treatment
- Identify the major adverse effects of inhaled corticosteroids, SABAs, and LAMAs, and how each is managed
- Recognise the correct inhaler technique counselling points, including when a spacer is indicated
Core concepts
Why the drug backbones differ
Asthma and COPD can look similar on presentation, but they're mechanistically different conditions, and that difference drives every step of their respective treatment ladders. Asthma is fundamentally chronic airway inflammation (often eosinophilic) with bronchial hyperresponsiveness, and the airflow obstruction is largely reversible — so the controller backbone is an inhaled corticosteroid (ICS), which treats the underlying inflammation, with a β2-agonist to relax the acute smooth-muscle spasm. COPD is largely fixed airflow obstruction (neutrophilic inflammation, emphysema) that responds poorly to steroids — so its backbone is long-acting bronchodilators (LAMA/LABA), with ICS added only in specific phenotypes and at a real added pneumonia-risk cost.
The current GINA approach to asthma treatment
GINA's current strategy prioritises an anti-inflammatory reliever (AIR) approach for adults and adolescents, moving away from SABA-only relief. Track 1 — the preferred approach — uses low-dose ICS-formoterol as both the as-needed reliever (AIR) at the mildest end of severity, and as maintenance-and-reliever therapy (MART) as severity escalates, meaning the same inhaler is used both for daily control and for symptom relief. Track 2 is an alternative pathway using ICS-SABA as the as-needed reliever, requiring clear patient education on using two separate inhalers correctly. Compared with SABA-only reliever use, as-needed ICS-formoterol has been shown to meaningfully reduce severe exacerbations and reduce reliance on oral corticosteroids.
Drug classes at a glance
- SABA (short-acting β2 agonist) — e.g. salbutamol — fast-onset bronchodilation, the classic "reliever"
- LABA (long-acting β2 agonist) — e.g. salmeterol, formoterol — maintenance bronchodilation, used with ICS in asthma
- ICS (inhaled corticosteroid) — e.g. budesonide, fluticasone — anti-inflammatory; the asthma controller backbone
- LAMA (long-acting muscarinic antagonist) — e.g. tiotropium — the COPD maintenance backbone
- LTRA (leukotriene receptor antagonist) — e.g. montelukast — an add-on option, particularly useful in aspirin-sensitive asthma
Clinical application
Reading a scenario for the right diagnosis-to-drug logic
A scenario describing a young patient with intermittent, reversible symptoms and a clear allergic/exercise trigger is pointing toward asthma and an ICS-based answer. A scenario describing an older patient, a significant smoking history, and progressive, largely irreversible breathlessness is pointing toward COPD and a LAMA/LABA-based answer, with ICS reserved for patients meeting specific criteria (e.g. frequent exacerbations, a specific eosinophil count) rather than added routinely.
Inhaler technique — the counselling points OPRA tests
- Shake a pressurised metered-dose inhaler (pMDI) before use.
- If both a bronchodilator and an ICS are used via separate inhalers, the bronchodilator is taken first, with a short wait before the ICS.
- A spacer device improves lung deposition and is particularly recommended for children, older patients, or anyone with poor inhaler coordination.
- Rinse the mouth and gargle after ICS use to reduce the risk of oral candidiasis.
Common mistakes
- Treating asthma and COPD as needing the same first-line drug logic, when their underlying mechanisms — and therefore their backbone drug choice — are different.
- Assuming ICS should be added routinely in COPD, when current guidance reserves it for specific higher-risk patients because of an associated pneumonia-risk increase.
- Forgetting that beta-blockers (including some eye drop formulations) can precipitate bronchoconstriction in asthma, and not asking about respiratory history before their use.
- Not counselling on mouth-rinsing after ICS use, missing a simple, effective way to reduce oral candidiasis risk.
Exam tips
- • If a stem specifically contrasts a reversible vs an irreversible obstruction pattern (e.g. spirometry response to a bronchodilator), that's testing the asthma-vs-COPD distinction directly — use it to anchor which drug ladder applies.
- • Watch for a scenario mentioning frequent exacerbations or a specific eosinophil count in a COPD patient — that's the signal that ICS add-on is actually being tested as appropriate here, not a default answer.
Memory tricks
- • "Asthma: treat the inflammation. COPD: open the airway." — a short line capturing why ICS is central in asthma but only conditionally added in COPD.
Clinical pearls
- 💡 The shift toward ICS-formoterol as both reliever and maintenance therapy (rather than a SABA-only reliever) reflects evidence that SABA-only treatment is associated with increased exacerbation risk and worse outcomes with overuse — a change in thinking worth understanding the reasoning behind, not just memorising as a rule.
Tables
Asthma vs COPD — key distinguishing features
| Feature | Asthma | COPD |
|---|---|---|
| Airflow obstruction | Largely reversible | Largely fixed/irreversible |
| Typical onset | Childhood or young adult | Usually over 40, strong smoking history |
| Key trigger | Allergens, exercise | Smoking (the dominant cause) |
| Treatment backbone | Inhaled corticosteroid (ICS) | Long-acting bronchodilator (LAMA/LABA) |
Key adverse effects and management
| Drug/class | Key adverse effect | Management |
|---|---|---|
| ICS (inhaled) | Oral candidiasis, dysphonia | Rinse mouth after use; use a spacer |
| Salbutamol (SABA) | Tremor, tachycardia, hypokalaemia | Reassure; dose review if excessive use |
| Tiotropium (LAMA) | Dry mouth, urinary retention | Caution in benign prostatic hyperplasia/glaucoma |
| Fluticasone ICS in COPD | Increased pneumonia risk in frequent exacerbators | Reserve for patients meeting specific criteria |
Practice MCQs (100% original)
1. Why is an inhaled corticosteroid the core controller therapy in asthma but only a conditional add-on in COPD?
2. Under the current GINA anti-inflammatory-reliever approach, what does Track 1 (the preferred pathway) use as both the as-needed reliever and the maintenance therapy?
3. A patient using an inhaled corticosteroid develops oral candidiasis. What counselling point, if followed correctly, would most likely have reduced this risk?
Ready to practise this topic?
Try original OPRA-style questions with detailed, option-by-option explanations — free to start.
Start freeFrequently asked questions
Is SABA-only treatment (e.g. salbutamol alone) still recommended for asthma?
Current GINA guidance recommends against SABA-only treatment for asthma in adults and adolescents, favouring an anti-inflammatory reliever approach instead, because SABA-only use is associated with increased exacerbation risk and worse outcomes when relied on alone.
Why do asthma and COPD sometimes get treated with the same drug classes if their mechanisms differ?
There's overlap in the toolkit — both conditions can involve bronchodilators, for example — but the emphasis and the reasoning differ. Asthma treatment is built around an anti-inflammatory backbone with bronchodilation for symptom relief, while COPD treatment is built around bronchodilation as the primary backbone, with anti-inflammatory therapy added only for specific higher-risk patients.
Official references
- Global Initiative for Asthma (GINA) — Strategy Report ↗ — Current international asthma management strategy
- Therapeutic Guidelines Australia — Respiratory ↗ — Australian-specific respiratory treatment guidance
- Australian Medicines Handbook ↗ — Drug-specific dosing, monitoring and adverse effect detail